Global Antibody Drug Conjugates Market, By Product Type [Adcetris, Kadcyla, Enhertu, Trodelvy, Padcev, and Others (Blenrep, Tivdak, Zynlota, Elahere, etc.)], By Linker Type (Non-cleavable Linker and Cleavable Linker), By Application [Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others (Renal Caner, Urothelial & Bladder Cancer, Etc.], By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 5.38 Billion in 2023 and is expected to exhibit a CAGR of 14.2% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The key market players are focusing on adopting growth strategies, such as collabortions, which is anticipated to drive the global antibody drug conjugates market growth over the forecasted period. For instance, in December 2022, Merck, a multinational pharmaceutical corporation, and Kelun-Biotech, a clinical-stage biotech company, announced a collaboration and exclusive licensing agreement to develop seven investigational preclinical Antibody-drug Conjugates (ADC) for cancer treatment. Kelun-Biotech has awarded Merck exclusive global licenses to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies, as well as exclusive options to obtain further licenses to ADC candidates, under the terms of the agreement.
Global Antibody Drug Conjugates Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation from one place to another.
COVID-19 had a significant impact on the global antibody drug conjugates market. According to an article published in February 2021 by American Cancer Society, there was a 52% decrease in the diagnosis of breast cancer and a 25% decrease in the diagnosis of pancreatic cancer in the U.S. between March 2020 and April 2020, as compared to January 2020 and February 2020. As a result, the pandemic affected the ongoing research and development of potential antibody drug conjugates.
Global Antibody Drug Conjugates Market: Key Developments
On July 10, 2023, BeiGene, a biotechnology company, and DualityBio, a clinical stage company, announced a collaboration in which BeiGene would acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with selected solid tumors. DualityBio will receive an upfront payment and will be eligible for additional payments based on the achievement of certain development, regulatory, and commercial milestones, totaling up to US$ 1.3 billion, in addition to tiered royalties, under the terms of the agreement.
On April 18, 2023, Sutro Biopharma, Inc., a clinical-stage oncology company, announced enhanced preclinical data for STRO-003, its ROR1 targeting ADC, presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held from April 14-19, 2023 in Orlando, U.S. STRO-003 is a new, next-generation ADC that targets ROR1 and attaches to -glucuronide-exatecan linker-payloads via site-specific conjugation methods, achieving a drug-antibody-ratio (DAR) of eight.
On March 30, 2023, AstraZeneca, a multinational pharmaceutical and biotechnology company, announced the completion of an exclusive global license agreement for CMG901, a potential first-in-class Antibody Drug Conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers, with KYM Biosciences Inc., a joint venture established by affiliates of Keymed Biosciences, a biotechnology company, and Lepu Biopharma, an innovation-driven biopharmaceutical company. CMG901 is now being tested in a Phase I trial for the treatment of Claudin 18.2-positive solid tumors including gastric cancer.
In February 2022, Adcentrx Therapeutics, a biotechnology company, and AvantGen, a pioneer in the use of yeast display technology for human antibody discovery and optimization, announced a three-year, multi-target collaboration to discover antibodies that would be developed into innovative ADC therapeutic candidates. Adcentrx Therapeutics will specify targets against which AvantGen would screen for new antibodies using its yeast display method under the terms of the collaboration.
Browse 44 Market Data Tables and 42 Figures spread through 180 Pages and in-depth TOC on “Global Antibody Drug Conjugates Market”- Forecast to 2030, Global Antibody Drug Conjugates Market, By Product Type [Adcetris, Kadcyla, Enhertu, Trodelvy, Padcev, and Others (Blenrep, Tivdak, Zynlota, Elahere, etc.)], By Linker Type (Non-cleavable Linker and Cleavable Linker), By Application [Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others (Renal Caner, Urothelial & Bladder Cancer, etc.], By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/antibody-drug-conjugates-market-181
Key Takeaways of the Global Antibody Drug Conjugates Market:
- The global antibody drug conjugates market is expected to exhibit a CAGR of 14.2% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global antibody drug conjugates market.
- Among product type, the Kadcyla segment is expected to hold the second highest share in the global antibody drug conjugates market during the forecast period owing to the rising number of research and development activities. For instance, on August 8, 2023, Seagen Inc., a biotechnology company, stated that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA (tucatinib) in combination with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla) met its primary endpoint of Progression-free Survival (PFS). Patients in the trial had unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer and had previously had treatment with a taxane and trastuzumab.
- Among region, North America is expected to be the dominant region in the global antibody drug conjugates market owing to inorganic strategies such as collaboration adopted by key market players. For instance, on June 8, 2023, Lantern Pharma Inc., a clinical-stage biopharmaceutical company, announced a research collaboration with Bielefeld University (Bielefeld, Germany) to develop Antibody-drug Conjugates (ADCs) with high therapeutic and anticancer potential using its Artificial Intelligence (AI) platform, RADR. The collaboration's outcomes are intended to pave the way for next-generation ADCs and other drug conjugates to be developed with potentially higher efficacy, at a faster pace, and at significantly reduced costs.
- The major players operating in the global antibody drug conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd
